Phosphine

Phosphine

SCHEMBL241499

P.c1ccc2c(c1)CCCN2

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
TSHR P16473 1/20 0.46
KDM4E B2RXH2 3/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
ALOX15 P16050 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
CASP1 P29466 1/20 0.42
HTT P42858 1/20 0.42
CASP7 P55210 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 1/20 0.42
MAPK13 O15264 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29370549 0.98 MAPT (0.50) MAPTTSHRKDM4ECA12CA1
SCHEMBL27392334 0.98 MAPT (0.50) MAPTTSHRKDM4ECA12CA1
SCHEMBL18172 0.98 MAPT (0.50) MAPTTSHRKDM4ECA12CA1
SCHEMBL517747 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1
Hydrochloric Acid SCHEMBL30018404 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1
Methane SCHEMBL11211553 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1
Cyclopropane SCHEMBL29291393 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1
SCHEMBL7259924 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1
SCHEMBL8215775 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1
Hydrochloric Acid SCHEMBL5370795 0.95 MAPT (0.48) MAPTTSHRKDM4ECA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0385271-A1 Tetrahydroquinolines and method of preparation EASTMAN KODAK COMPANY (US) 1990-09-05 EP claimed
EP-2076524-B1 CHIRAL PHOSPHORUS COMPOUND JOHNSON MATTHEY PLC (GB) 2016-04-20 EP disclosed
US-8735583-B2 Chiral phosphorus compound JOHNSON MATTHEY PUBLIC LIMITED CO. (GB) 2014-05-27 US disclosed
US-20130150583-A1 CHIRAL PHOSPHORUS COMPOUND JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2013-06-13 US disclosed
US-8404843-B2 Chiral phosphorus compound JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2013-03-26 US disclosed
US-20120264940-A1 CHIRAL PHOSPHORUS COMPOUND JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-10-18 US disclosed
US-8222415-B2 Chiral phosphorus compound JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-07-17 US disclosed
US-20120004411-A9 CHIRAL PHOSPHORUS COMPOUND JOHNSON MATTHEY PLC (GB) 2012-01-05 US disclosed
US-20100240898-A1 CHIRAL PHOSPHORUS COMPOUND JOHNSON MATTHEY PLC (GB) 2010-09-23 US disclosed
EP-2076524-A1 CHIRAL PHOSPHORUS COMPOUND Johnson Matthey Public Limited Company (GB) 2009-07-08 EP disclosed
WO-2008041029-A1 CHIRAL PHOSPHORUS COMPOUND JOHNSON MATTHEY PLC (GB) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264940-A1 CHIRAL PHOSPHORUS COMPOUND PIK3CA, RECQL, P2RY1 MAPT 4310/4885TSHR 1983/4885KDM4E 3774/4885
US-20120004411-A9 CHIRAL PHOSPHORUS COMPOUND PIK3CA, RECQL, P2RY1 MAPT 4310/4885TSHR 1983/4885KDM4E 3774/4885
US-20100240898-A1 CHIRAL PHOSPHORUS COMPOUND PIK3CA, RECQL, P2RY1 MAPT 4310/4885TSHR 1983/4885KDM4E 3774/4885
US-20130150583-A1 CHIRAL PHOSPHORUS COMPOUND ALPP, PTH1R, CALCR MAPT 4361/4885TSHR 818/4885KDM4E 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.